Open AccessDevelopment and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood
Author(s) -
Ying Qu,
Gaëlle Noé,
Autumn Breaud,
Michel Vidal,
William Clarke,
Noël Zahr,
Thierry Dervieux,
Nathalie Costédoat-Chalumeau,
Benoı̂t Blanchet
Publication year - 2015
Publication title -
future science oa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 23
ISSN - 2056-5623
DOI - 10.4155/fso.15.24
Subject(s) - hydroxychloroquine , protein precipitation , high performance liquid chromatography , pharmacology , whole blood , therapeutic drug monitoring , medicine , chromatography , drug , chemistry , pharmacokinetics , covid-19 , disease , infectious disease (medical specialty)
Background: Therapeutic drug monitoring for hydroxychloroquine (HCQ) has been suggested to assess nonadherence and optimize treatment efficacy in systemic lupus erythematosus patients. Materials & methods: After protein precipitation, HCQ and its metabolites, desethylhydroxychloroquine and desethylchloroquine were separated on a phenyl column and monitored by fluorescence detection. The method was linear from 50 to 4000 ng/ml for HCQ. The intra-day and inter-day precision of HCQ, desethylhydroxychloroquine and desethylchloroquine ranged from 4.3 to 10.3%. LLOQ was 50 ng/ml for HCQ. Conclusion: The method is very practical and was applied to routinely monitor the steady state whole blood exposure of HCQ and its metabolites in systemic lupus erythematosus patients. It well correlated with our LC–MS/MS and another HPLC method.